ArticleCurrent infectious disease reports2012
HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.
Article in Current infectious disease reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.Frontiers in immunology · 2025Article
- Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis.Mediators of inflammation · 2020Article
- Simvastatin ameliorates oxygen glucose deprivation/reoxygenation-induced pulmonary endothelial barrier dysfunction by restoring cell-cell junctions and actin cytoskeleton dynamics via the PI3K/Akt signaling pathway.American journal of translational research · 2020Article
- Lipid profile and statin use in critical care setting: implications for kidney outcome.Einstein (Sao Paulo, Brazil) · 2019Article
- Is There Potential for Repurposing Statins as Novel Antimicrobials?Antimicrobial agents and chemotherapy · 2016Review
- Chronic Statin Use and Long-Term Rates of Sepsis: A Population-Based Cohort Study.Journal of intensive care medicine · 2016Article
- Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis.Experimental and therapeutic medicine · 2015Article
- Simvastatin does not reduce chemokine production in obesity without comorbidities.Inflammation · 2015Article
- The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HMG-CoA reductase inhibitors, or statins, are among the most commonly prescribed pharmaceuticals in the world, especially among the elderly. The remarkable conjuncture of this fact with the rising incidence of severe sepsis among people over age 65 could prove to be of serendipitous benefit, because numerous actions of the statins make them of potential use in the prevention and treatment of severe sepsis. Severe sepsis continues to be a highly lethal condition, for which there are, as yet, no effective pharmacological treatments, save antibiotics. We explore the biological plausibility of statins as prophylaxis agents and as treatment for severe sepsis and thoroughly review the preclinical and clinical studies that have explored the effects of statins in infected and septic patients. Statins remain only promising treatments for severe sepsis, without convincing evidence that they reduce patient mortality. Ongoing randomized trials may provide conclusive evidence, whether positive or negative.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.